Blood transfusion experience for cyclosporine/prednisone-treated renal allograft recipients at the University of Texas Medical School at Houston.
Our data indicate that CsA-P-treated primary recipients of cadaveric donor renal allografts as well as haploidentical living-related donor allograft recipients enjoy prolonged, successful patient and graft survivals whether conditioned with pretransplant transfusions or not. The data are important because they reflect clinical results from a single transplant center wherein the recipients have been immunosuppressed for approximately 7 years with little change in protocol. This is an important point since utilizing maximum therapeutic immunosuppressive efficacy will result in prolonged graft and patient survival.